iiinova — where your digital self keeps evolving

Mineralys Therapeutics @mineralystx.com · 22h

New data from the Launch-HTN trial of lorundrostat will be presented during an oral session at the American Society of Nephrology Kidney Week 2026, taking place October 21-25 in Denver, Colorado. Learn more: ir.mineralystx.com/news-events/... #KidneyWk #Hypertension #CKD @asnkidney.bsky.social

PRESS RELEASE
Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026

010

Mineralys Therapeutics @mineralystx.com · 01/10/2026

We will present five abstracts at the upcoming American Heart Association Hypertension Scientific Sessions 2026, taking place October 7-11 in Arlington, VA. Details: ir.mineralystx.com/news-events/... #Hypertension26 #BloodPressure #CardioRenalMetabolic #ClinicalResearch @ahascience.bsky.social

PRESS RELEASE
Mineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026

000

Mineralys Therapeutics @mineralystx.com · 29/09/2026

Today is #WorldHeartDay. High blood pressure affects nearly half of U.S. adults and often shows no symptoms, yet it raises the risk of heart disease and stroke. #DontMissABeat #KnowYourNumbers and talk to your provider. #Hypertension #HeartHealth

Top left copy reads: NO SYMPTOMS DOESN’T MEAN NO RISK. CHECK YOUR BLOOD PRESSURE.
Below is an image of two people sitting at a table. The woman (healthcare provider) is wearing a white coat with a stethoscope around her neck. She is fitting wrapping a blood pressure cuff around the arm of a man wearing a grey shirt.
There is a cartoon/icon of a heart in the bottom right corner.

001

Mineralys Therapeutics @mineralystx.com · 24/09/2026

New long-term efficacy and safety data from our ongoing Transform-HTN open-label extension trial of lorundrostat will be featured in a late-breaking science presentation on Sunday, November 8, at the American Heart Association #ScientificSessions26 in Chicago, IL.

PRESS RELEASE
Mineralys Therapeutics’ Transform-HTN Open-Label Extension Trial Data Selected for Late-Breaking Presentation at American Heart Association Scientific Sessions 2026

110

Mineralys Therapeutics @mineralystx.com · 17/09/2026

It’s #HealthyAging Month, a good reminder to get your blood pressure checked. #Hypertension increases the risk of heart disease, heart attack, and stroke - leading causes of death in the U.S. Schedule regular check-ins with your healthcare provider and #KnowYourNumbers #CardioSky

Graphic shows a female healthcare provider taking the blood pressure of a male patient.
COPY READS: September is Health Aging Month. Know your numbers.

010

Mineralys Therapeutics @mineralystx.com · 21/08/2026

On #NationalSeniorCitizensDay, we recognize the wisdom and contributions of older adults. Managing #bloodpressure is an important part of healthy aging and can help protect long-term heart, kidney, and brain health. Encourage an older loved one to know their numbers. #HeartHealth #CardioSky

010

Mineralys Therapeutics @mineralystx.com · 17/08/2026

Healthy habits support #bloodpressure, yet for many people it stays high even with lifestyle changes and standard medicines. Dysregulated #aldosterone drives ~30% of #hypertension. This #NationalWellnessMonth, know your numbers and understand your drivers.

Know Your Numbers.
Understand your drivers.

Three icons on below (from left):
1. sphygmomanometer
2. cup of water (to represent fluid balance)
3. person running on treadmill

010

Mineralys Therapeutics @mineralystx.com · 31/07/2026

#DYK extreme heat can affect the body’s fluid balance, electrolytes, and #bloodpressure? Aldosterone, a hormone produced by the adrenal glands, helps regulate sodium and water balance, which is essential for maintaining blood volume and blood pressure. ☀️

Graphic shows 5 circles with a series of icons and arrows in between point to the next. FROM LEFT:
1. Icons of a red sun and thermometer. Copy below reads: HEAT: Raises core body temperature
2. Icon of person with water droplets near the head. Copy below reads: SWEATING: Depletes fluid and sodium.
3. Icon of a scale with water droplets on the left and red circle with the letters “Na” inside. Copy below reads: ELECTROLYTE SHIFTS: Disrupts sodium & water balance.
4. Icon of a molecule. Copy below reads: ALDOSTERONE: Helps regulate balance.
5. Icon of a sphygmomanometer with a heart in the center. Copy below reads: BLOOD PRESSURE: May be harder to control when aldosterone is dysregulated.

110

Mineralys Therapeutics @mineralystx.com · 14/07/2026

Every hour, high #bloodpressure contributes to 1,000+ deaths from stroke and heart attack globally. Summer heat adds strain, so try to prioritize hydration, avoid prolonged heat exposure, & consult your #HCP on #hypertension management as temperatures climb. #CRMS #PublicHealth #CardioSky

Graphic with dark blue background and a sun in the top right corner.
Copy reads (from top):

High blood pressure
is a year-round risk.

Extreme heat can add
cardiovascular stress.

Icon of water drop: Stay hydrated
Icon with a sun and a thermometer: Limit prolonged heat exposure
Icon of a stethoscope with a heart in the center: Talk to a healthcare professional

020

Mineralys Therapeutics @mineralystx.com · 01/07/2026

Research links chronic stress, anxiety, and depression to ⬆️ #hypertension risk in #BIPOC populations. Mental & emotional health are part of the cardiovascular risk conversation. Mineralys is committed to research that reflects the diversity of populations most affected by #bloodpressure disparities.

Left side of graphic has a dark blue background with the following text:
JULY IS
BIPOC Mental Health Awareness Month
Chronic stress, anxiety, and depression
have been associated with a higher incidence
of hypertension in BIPOC populations.
Know your numbers,
talk to your doctor.

On the right side is an image of three people of color (two women and one man) sitting at a table smiling

010

Mineralys Therapeutics @mineralystx.com · 24/06/2026

A new literature review adds to the growing evidence linking dysregulated #aldosterone to #hypertension and to cardiovascular, kidney, and metabolic disease. At Mineralys, we’re targeting it directly. #CRMS #CardioSky #NephSky

Left side of graphic features a circle with the words “Dysregulated aldosterone” in the center and 4 icons on the perimeter (from the top, clockwise):
- Hypertension with sphygmomanometer icon and heart
- Cardiovascular disease with heart icon
- Kidney disease with kidney icon
- Metabolic diseases with icon of a person

Copy on the right reads:
A new literature review adds to the growing evidence linking dysregulated aldosterone to organ damage, including hypertension, cardiovascular, kidney, and metabolic diseases.

120

Mineralys Therapeutics @mineralystx.com · 15/06/2026

#HighBloodPressure isn’t just a later-life concern. For U.S. adults 18-39, #hypertension is nearly twice as common in men than women. Know your numbers this #MensHealthWeek. #MensHealthMonth

Know Your Numbers
White circle below has an icon of a sphygmomanometer with a red heart in the center.

010

Mineralys Therapeutics @mineralystx.com · 14/06/2026

We presented a new post hoc analysis on the effect of lorundrostat on #heartfailure risk biomarkers from participants in our pivotal Launch-HTN & Advance-HTN trials during a late-breaking poster presentation at #ENDO2026. Read more: ir.mineralystx.com/news-events/... #CVD #Hypertension #Cardiosky

PRESS RELEASE
Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)

120

Mineralys Therapeutics @mineralystx.com · 10/06/2026

#DYK brain & cardiovascular health are linked? ~20% of the body’s blood supply flows to the brain. Chronic #HighBloodPressure can damage blood vessels and, over time, may contribute to cognitive decline.

110

Mineralys Therapeutics @mineralystx.com · 08/06/2026

A new post hoc analysis of proteomic data from the Launch-HTN and Advance-HTN trials of lorundrostat will be featured in a late-breaking poster presentation on June 14 at #ENDO2026. Read more: ir.mineralystx.com/news-events/... #Hypertension #LateBreakingData

Press Release
Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)

020

Mineralys Therapeutics @mineralystx.com · 05/06/2026

1 in 2 men in the U.S. are living with #hypertension. This Men's Health Month, Mineralys is focused on advancing cardiovascular research and the science of blood pressure control. #MensHealthMonth #HeartHealth #BloodPressureAwareness #CardioSky

Image of 4 men - two on left are screened in black and white and the two on the right are shown in color.
Text reads: 1 in 2 Men in the the U.S. are living with hypertension

010

Mineralys Therapeutics @mineralystx.com · 30/05/2026

We shared new data from a post hoc analysis of our Ph 3 Launch-HTN trial during an oral presentation at #ESH2026: in participants with #hypertension and #CKD, lorundrostat significantly reduced #bloodpressure, and among the subset with CKD and baseline albuminuria, UACR.

PRESS RELEASE
Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

130

Mineralys Therapeutics @mineralystx.com · 26/05/2026

The latest AHA/ACC guidelines from 2025 lowered the #hypertension treatment threshold. Earlier intervention saves lives, yet <50% of adults w/ high blood pressure have it under control, and the burden falls hardest on Black adults, women & the elderly. Know your numbers this #HighBloodPressureMonth.

Know Your Numbers
Image on left shows a sphygmomanometer with a heart icon in the center.
On the right in the purple text bubble: < 130/80 mmHg
Below it reads: The latest hypertension threshold per AHA/ACC guidelines.

020

Mineralys Therapeutics @mineralystx.com · 18/05/2026

New data from our Phase 3 Launch-HTN trial of lorundrostat in participants with hypertension and CKD will be featured in an oral presentation on Saturday, May 30th at #ESH2026 in Gdańsk, Poland. Read more: ir.mineralystx.com/news-events/... #Hypertension #CKD #ClinicalData #CardioSky #NephSky

PRESS RELEASE
Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

021

Mineralys Therapeutics @mineralystx.com · 17/05/2026

Today is #WorldHypertensionDay, a global reminder that hypertension control takes all of us. BP screenings and lifestyle education reduce the risk of stroke, heart disease, and kidney disease. Know your numbers. Protect your future. #WHD2026 #GlobalHealth #Hypertension #CardioSky

Top left: 2026 May 17
Controlling Hypertension Together
Initiated by the World Hypertension League WHLeague.org
Top right: World Hypertension Day

Center image of a doctor taking a patient’s blood pressure seated at a table
Below image:
Know Your Numbers.
Protect Your Future.
BP screenings and lifestyle education reduce stroke, heart disease and kidney disease risks.

010

Mineralys Therapeutics @mineralystx.com · 11/05/2026

It’s #NationalWomensHealthWeek & #WomensCheckupDay. Women, especially those with obesity or diabetes, face a disproportionate burden of treatment-resistant #hypertension, and #aldosterone is frequently an overlooked driver. Get your #bloodpressure checked. Ask what's behind it. #CardioSky

Image depicts a healthcare interaction between two women: The woman on the left is wearing a blue shirt (patient) has a blood pressure cuff on her arm. The woman on the right is wearing a white coat with a stethoscope around her neck (doctor) and is looking at her patient.

Copy in white box reads:
> Get your checkup.
> Know your blood pressure.
> Ask what’s behind it.

Copy in purple reads:
National Women’s Checkup Day | May 11

010

Mineralys Therapeutics @mineralystx.com · 04/05/2026

May is #HighBloodPressureMonth. Nearly half of U.S. adults have high blood pressure and many don't know it. Many sufferers have no symptoms. The first step: get your blood pressure checked. #Hypertension #HeartHealth #CardioSky

010

Mineralys Therapeutics @mineralystx.com · 28/04/2026

#CKD disproportionately affects racial and ethnic minority populations and is often underdiagnosed, with many individuals unaware of their disease. #MinorityHealthAwarenessMonth

LEFT: More than 1-in-10 (14%) adults aged 18 or older (37 million people) have CKD
Below 10 icons of people - the first colored red, the second partially colored red and the remainder all in grey

CENTER: Approximately 21% of adults in the US are living with both hypertension and CKD (superimposed on a map of the US) with a BP gauge icon and kidney icon below

RIGHT: CKD was more common in non-Hispanic Black adults (22%) than in non-Hispanic White adults (13%) or Hispanic adults (12%)
Pie chart below (clockwise)
RED 22% Non-Hispanic Black Adults
BLUE 13% Non-Hispanic White Adults
GREY 12% Hispanic Adults

110

Mineralys Therapeutics @mineralystx.com · 23/04/2026

It’s #AdrenalAwarenessMonth. Aldosterone, produced in the adrenal glands, regulates #bloodpressure. Some people with #hypertension have dysregulated #aldosterone - a key driver of uncontrolled or resistant hypertension & #CRMS. At Mineralys, we're targeting it directly. #CardioSky #NephSky

Aldosterone is a steroid hormone that regulates blood pressure and blood volume
Purple bar: Aldosterone dysregulation is associated with
Below from left:
- Sphygmomanometer icon: Hypertension (including resistant hypertension)
- Heart icon: Heart failure
- Kidneys icon: Chronic kidney disease
- Brain with spot: Stroke

010

Mineralys Therapeutics @mineralystx.com · 20/04/2026

We’re proud to share a major milestone: our publication in Clinical and Translational Science has been named a Top 10 most-cited paper of 2024. This recognition reflects the impact of our work in advancing translational science. 🚀 #Hypertension #ClinicalResearch

Graphic of journal cover:
Top right: An Official Journal of ASCPT
TITLE: CTS Clinical and Translational Science
Open Access (on right in Green bubble)

Title of article superimposed on journal cover: First-in-human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitor.

Circle at right side: Top cited article Wiley 2025

110

Mineralys Therapeutics @mineralystx.com · 14/04/2026

This #MinorityHealthMonth, we recognize #hypertension as a critical public health issue affecting millions - but not equally. Despite treatments, racial & ethic groups have undiagnosed or poorly controlled hypertension, leading to considerable health risks and economic burden.

Hypertension prevalence by race/ethnicity in the US
Image of the U.S. map in purple with 3 circles - from left:
47% White Adults
44% Hispanic Adults
59% Black Adults
Text on the right side of the “map” reads: Racial and ethnic populations are disproportionately impacted by hypertension

131

Mineralys Therapeutics @mineralystx.com · 28/03/2026

If you’re attending #ACC26, stop by & connect with our Med Affairs team to learn more about our focus on aldosterone biology in #hypertension and CRM diseases. 📍Booth #1150 We hope to see you! #HighBloodPressure #CKD #NOLA

010

Mineralys Therapeutics @mineralystx.com · 24/03/2026

#DYK that both #hypertension and reduced kidney function are among risk factors for cardio-renal-metabolic (CRM) syndrome - a disorder attributable to connections among heart disease, kidney disease, diabetes, & obesity.

Hypertension and reduced kiney function are among the risk factors for cardio-renal-metabolic (CRM) syndrome

Graphic with the words "Cardio-Renal-Metabolic Syndrome” inside a circle depicting the risk factors (from top - clockwise): Excess weight with icon of overweight person; Reduced kidney function with icon of kidneys; High blood sugar with icon of glucose monitor; High cholesterol with icon of droplet and arrow pointing up; High blood pressure with a heart and icon of sphygmomanometer

140

Mineralys Therapeutics @mineralystx.com · 24/03/2026

We are thrilled to announce the appointment of Jeffrey A. Munsie as Mineralys’ Chief Legal Officer. Read more: ir.mineralystx.com/news-events/... #Hypertension $MLYS

Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer

120

Mineralys Therapeutics @mineralystx.com · 12/03/2026

Today we reported financial results for the fourth quarter and full year ending December 31, 2025, and provided a corporate update. Learn more: ir.mineralystx.com/news-events/... #Hypertension #ChronicKidneyDisease $MLYS

Mineralys Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

220

Mineralys Therapeutics @mineralystx.com · 09/03/2026

The U.S. FDA has accepted our NDA for lorundrostat for the treatment of adult patients with other antihypertensive drugs and set a PDUFA date of Dec. 22. Also announced were topline results from the P2 Explore-OSA exploratory trial. Details here: ir.mineralystx.com/news-events/... #Hypertension

Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for the Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results

010

Mineralys Therapeutics @mineralystx.com · 26/02/2026

As American Heart Month wraps up, it’s worth remembering that heart health is bigger than the heart alone. Mineralys Therapeutics is taking a targeted approach to hypertension and cardio-renal-metabolic disease by addressing a key driver, aldosterone. #CRM #HeartHealth #HeartMonth

Graphic with headline: The Heart is central to Cardiometabolic Health

Image shows center circle with the world Aldosterone and 6 circles around it including (clockwise):
Obese Uncontrolled Hypertension
Treatment Resistant Hypertension
Chronic Kidney Disease
Vascular & Systemic Inflammation
HFpEF & HFrEF
Obstructive Sleep Apnea

010

Mineralys Therapeutics @mineralystx.com · 11/02/2026

In February we honor #HeartMonth, as well as #CardiovascularProfessionalsWeek. Mineralys celebrates the dedicated individuals working tirelessly on the prevention, diagnosis, treatment and rehabilitation of heart and vascular diseases.

Cardiovascular Professionals Week
February 8-15, 2026
Image of a stethoscope and heart.

030

Mineralys Therapeutics @mineralystx.com · 04/02/2026

February is American #HeartMonth ❤️ Despite the availability of effective therapies for #hypertension, treatment and control rates have stalled and related CV death rates in the U.S. have nearly doubled in 20 years. At Mineralys, we’re advancing science to change this trajectory. #KnowYourNumbers

010

Mineralys Therapeutics @mineralystx.com · 22/01/2026

Our CEO spoke with @firstwordgroup.com about how Mineralys is reviving innovation in #hypertension by targeting aldosterone, what differentiates the company’s approach, and where lorundrostat could play a role in cardiorenal & metabolic disease. Read the interview: firstwordpharma.com/story/7067623

020

Mineralys Therapeutics @mineralystx.com · 20/01/2026

This week is the @americanheart.bsky.social's #HealthyWeightWeek. #Obesity & #hypertension often coexist, and dysregulated aldosterone is frequently observed in patients with uncontrolled or treatment-resistant hypertension and in patients with obesity.

The link between obesity, aldosterone and hypertension

120

Mineralys Therapeutics @mineralystx.com · 06/01/2026

Today we issued a corporate update highlighting several recent and upcoming clinical & regulatory milestones. Mineralys' management team will also participate in the LifeSci Partners Corporate Access event taking place January 12-14 in San Francisco. ir.mineralystx.com/news-events/... #HTN #MLYS

Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026

020

Mineralys Therapeutics @mineralystx.com · 31/12/2025

2025 was an exciting year for Mineralys! We are grateful to everyone who contributed to our journey to advance Lorundrostat’s development in #HTN, #CKD and #OSA.

010

Mineralys Therapeutics @mineralystx.com · 12/12/2025

Our P3 Launch-HTN trial of lorundrostat - the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension - was featured in JAMA’s inaugural “Research of the Year” article! ir.mineralystx.com/news-events/... #JAMAROTY25

043

Mineralys Therapeutics @mineralystx.com · 07/11/2025

We shared data from the P2 Explore-CKD trial during a late-breaking oral presentation at #KidneyWk. The parallel reductions in systolic blood pressure & albuminuria underscore lorundrostat's potential to improve cardio-renal outcomes in this high-risk population. ir.mineralystx.com/news-events/...

PRESS RELEASE

Data for Lorundrostat
in Chronic Kidney Disease and
Hypertension Presented at American Society of Nephrology
(ASN) Kidney Week 2025

130

Mineralys Therapeutics @mineralystx.com · 07/11/2025

If you’re attending #AHA25, stop by & connect with our Medical Affairs team to learn more about our focus on aldosterone biology in CRM diseases. 📍Booth #4216 And join us Saturday in Heart Theater 1 for a discussion on the unmet need in uncontrolled #hypertension. We hope to see you!

AHA Scientific Sessions
November 8-10 | New Orleans, LA
Booth 4216

Dysregulated Aldosterone in Uncontrolled Hypertension: The Overlooked Risk Factor and New Therapeutic Options
Saturday, November 8, 2025
9:30 AM - 10:15 AM in Heart Theater 1

Unmet Need in Uncontrolled and Resistant Hypertension
Michael Bloch, MD
Clinical Associate Professor and Medical Director, University of Nevada/Reno School of Medicine, Renown Institute for Heart and Vascular Health

Role of Aldosterone Dysregulation and Impact on Hypertension and Beyond
Jorge Plutzky, MD
Director, Preventive Cardiology
Harvard Medical School
Cardiovascular Medicine

Efficacy & Safety of Novel ASI, Lorundrostat from Launch-HTN study
Manish Saxena, MBBS
Clinical Director, Barts Health NHS Trust & Queen Mary University London, UK

020

Mineralys Therapeutics @mineralystx.com · 06/11/2025

If you’re in #Houston for @asnkidney.bsky.social #KidneyWk, join us tomorrow in Grand Ballroom C at the Convention Center to catch our #latebreaking presentation. We hope to see you there! #Hypertension #CKD #KidneyCare

LATE-BREAKING RESEARCH
Lorundrostat, a Novel Aldosterone Synthase Inhibitor (ASI), in Participants with Uncontrolled Hypertension, CDK, and Albuminuria: Results from Explore-CKD
November 7th | 5:06 PM to 5:18 PM CST
Grand Ballroom C, Convention Center

140

Mineralys Therapeutics @mineralystx.com · 30/10/2025

#Hypertension remains the leading modifiable risk factor for #CVD, despite decades of therapeutic efforts. Aldosterone dysregulation is increasingly recognized as a missing piece of the puzzle. Read: www.statnews.com/sponsor/2025... #CardioSky #NephSky

"Mineralys' singular focus on aldosterone biology and its nimble, patient-driven culture position it as a company determined not just to participate in this shift, but to lead it"
-Jon Congleton
CEO of Mineralys Therapeutics

030

Mineralys Therapeutics @mineralystx.com · 29/10/2025

Our team was in #Detroit with Black Girls RUN! & Dr. John Flack who discussed health equity and how black women can prioritize healthy living. Mineralys is focused on improving outcomes for people with #hypertension, including high-risk populations, and was honored to be part of this event.

010

Mineralys Therapeutics @mineralystx.com · 21/10/2025

We will be presenting lorundrostat data from our Phase 2 Explore-CKD trial in a late-breaking session next month at @asnkidney.bsky.social #KidneyWk on Friday, November 7. Read our press release for details: ir.mineralystx.com/news-events/... #Hypertension #CKD #ClinicalData #MLYS

PRESS RELEASE
Mineralys Therapeutics Announces Late-Breaking Presentation of
Phase 2 Explore-CKD Trial of Lorundrostat at American Society of Nephrology (ASN) Kidney Week 2025

020

Mineralys Therapeutics @mineralystx.com · 30/09/2025

Today we announced completion of enrollment in Explore-OSA, our Phase 2 #clinicaltrial examining the efficacy, safety & tolerability of lorundrostat in participants with #OSA & #hypertension. Topline results are anticipated in Q1 2026. Read: ir.mineralystx.com/news-events/... #CardioSky #NephSky

Mineralys Therapeutics Completes Enrollment in Phase 2 Explore-OSA Trial of Lorundrostat in Obstructive Sleep Apnea and Hypertension

020

Mineralys Therapeutics @mineralystx.com · 30/09/2025

Hypertension or high blood pressure affects 1.4B people globally. It’s the most prevalent & modiﬁable risk factor of cardiovascular diseases. In the U.S., 70M+ people aged 30–79 years have uncontrolled #hypertension. #WorldHeartDay #HighBloodPressure ♥️

130

Reposted by Mineralys Therapeutics

WHO @who.int · 23/09/2025

New WHO report finds 1.4 billion people live with #hypertension. Hypertension is the number one risk factor for: ‼️ Heart attack ‼️ Stroke and can lead to: ‼️ Chronic kidney disease ‼️ Dementia Get your blood pressure checked today! Learn more 👉 bit.ly/4nikP8v

Text reads: “7 in 10 people living with hypertension do not have it under control. Get your blood pressure checked today.”

010030

Mineralys Therapeutics @mineralystx.com · 19/09/2025

In just 6 years, Mineralys advanced #lorundrostat, a potential first-in-class aldosterone synthase inhibitor, from concept to pivotal published trials in #hypertension and is now preparing for a pre-NDA meeting in Q4 2025. Learn more: www.thepharmaletter.com/pharmaceutic... #Innovation #MLYS

"Our vision is to lead in targeted therapies for aldosterone-driven cardio-renal-metabolic (CRM) disease. By targeting aldosterone dysregulation, we aim to meet a critical unmet need with a new mechanism in a field that has seen little innovation in over two decades."
-Jon Congleton
CEO of Mineralys Therapeutics

030